| Systemic Lupus Erythematosus Research | Lifetime | 28 | JP 1 | 99.79 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 18 | JP 1 | 99.77 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 27 | JP 1 | 99.83 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 120 | JP 3 | 99.70 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 91 | JP 1 | 99.68 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 63 | JP 7 | 99.48 |
| Biosimilars and Bioanalytical Methods | Lifetime | 27 | JP 1 | 99.06 |
| Cell Adhesion Molecules Research | Lifetime | 148 | JP 3 | 99.38 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 23 | JP 7 | 98.67 |
| Lymphoma Diagnosis and Treatment | Lifetime | 265 | JP 5 | 99.21 |
| Bone Metabolism and Diseases | Lifetime | 111 | JP 10 | 99.09 |
| T-cell and B-cell Immunology | Lifetime | 446 | JP 16 | 99.14 |
| Systemic Sclerosis and Related Diseases | Lifetime | 158 | JP 11 | 98.55 |
| Bone health and treatments | Lifetime | 245 | JP 14 | 98.72 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 274 | JP 10 | 97.98 |
| Neuroendocrine Tumor Research Advances | Lifetime | 581 | JP 42 | 98.09 |
| T-cell and Retrovirus Studies | Lifetime | 259 | JP 54 | 97.26 |
| Peripheral Neuropathies and Disorders | Lifetime | 261 | JP 16 | 97.88 |
| Proteoglycans and glycosaminoglycans research | Lifetime | 266 | JP 25 | 97.21 |
| Spondyloarthritis Studies and Treatments | Lifetime | 221 | JP 2 | 97.71 |
| Bone and Joint Diseases | Lifetime | 361 | JP 20 | 97.07 |
| Vasculitis and related conditions | Lifetime | 293 | JP 11 | 97.14 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 821 | JP 23 | 96.92 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 478 | JP 22 | 96.44 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 290 | JP 34 | 95.94 |
| Toxin Mechanisms and Immunotoxins | Lifetime | 739 | JP 47 | 94.65 |
| Eosinophilic Disorders and Syndromes | Lifetime | 866 | JP 70 | 94.47 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 844 | JP 79 | 92.36 |
| Biomarkers in Disease Mechanisms | Lifetime | 665 | JP 48 | 83.79 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 636 | JP 33 | 85.08 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 1 | JP 1 | 99.92 |
| T-cell and B-cell Immunology | 2021-2025 | 1 | JP 1 | 99.61 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 1 | JP 1 | 99.94 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 2 | JP 1 | 99.92 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 4 | JP 1 | 99.84 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 1 | JP 1 | 99.73 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 13 | JP 1 | 99.76 |
| Immune Cell Function and Interaction | 2021-2025 | 77 | JP 2 | 98.68 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 51 | JP 1 | 99.31 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 22 | JP 2 | 98.85 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 4 | JP 1 | 97.83 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 36 | JP 1 | 97.37 |
| Biosimilars and Bioanalytical Methods | 2021-2025 | 54 | JP 2 | 96.34 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 151 | JP 3 | 96.25 |
| Vasculitis and related conditions | 2021-2025 | 71 | JP 3 | 97.34 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 78 | JP 2 | 97.44 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 136 | JP 8 | 97.19 |
| Peripheral Neuropathies and Disorders | 2021-2025 | 165 | JP 10 | 95.23 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 166 | JP 16 | 91.70 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 458 | JP 30 | 92.05 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 543 | JP 12 | 88.40 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 306 | JP 12 | 88.35 |
| Diabetes and associated disorders | 2021-2025 | 799 | JP 12 | 86.85 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 399 | JP 28 | 85.82 |
| Liver Diseases and Immunity | 2021-2025 | 469 | JP 29 | 85.37 |
| Vitamin D Research Studies | 2021-2025 | 449 | JP 9 | 82.89 |
| Urticaria and Related Conditions | 2021-2025 | 444 | JP 34 | 85.80 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 814 | JP 20 | 84.58 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 577 | JP 36 | 83.95 |
| Bone Metabolism and Diseases | 2021-2025 | 454 | JP 41 | 80.26 |
| Drug-Induced Adverse Reactions | 2021-2025 | 448 | JP 27 | 78.86 |
| Bone health and treatments | 2021-2025 | 815 | JP 99 | 74.10 |
| Statistical Methods in Clinical Trials | 2021-2025 | 652 | JP 18 | 74.44 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 880 | JP 65 | 56.42 |
| Skin Diseases and Diabetes | 2021-2025 | 609 | JP 36 | 44.12 |